Cover Image
市場調查報告書

大腸癌:流行病學·基於患者的市場預測,治療流程,上市藥·開發平台藥物分析

Colorectal cancer: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365178
出版日期 內容資訊 英文 402 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
大腸癌:流行病學·基於患者的市場預測,治療流程,上市藥·開發平台藥物分析 Colorectal cancer: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年04月01日 內容資訊: 英文 402 Pages
簡介

本報告提供大腸癌治療藥市場相關調查分析,提供您市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:大腸癌

  • 摘要整理
  • 市場概要·趨勢
  • 手法·市場定義
  • Avastin (bevacizumab)
  • CPP-1X (eflornithine/sulindac)
  • Cyramza (ramucirumab)
  • Erbitux (cetuximab)
  • Imprime PGG
  • Keytruda (pembrolizumab)
  • Lonsurf (trifluridine/tipiracil)
  • Masitinib
  • MGN1703 (lefitolimod)
  • Ofev (nintedanib)
  • OncoVAX
  • Stivarga (regorafenib)
  • TS-1 (gimeracil/oteracil potassium/tegafur)
  • Vectibix (panitumumab)
  • Xilonix
  • Zaltrap (aflibercept)
  • 1次調查手法

治療:美國·日本·EU5個國家的大腸癌

  • 摘要整理
  • 疾病定義·診斷
  • 患者區分
  • 目前治療選擇
  • I期·II期
  • III期
  • IV期
  • 調查手法

流行病學:美國·日本·EU5個國家的大腸癌

  • 摘要整理
  • 疾病定義
  • 全球變動
  • 危險因素
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優點·缺點
  • 參考文獻

上市藥:大腸癌

  • 摘要整理
  • 產品概要
  • 其他上市藥
  • 產品簡介:Avastin
  • 產品簡介:Camptosar
  • 產品簡介:Cyramza
  • 產品簡介:Eloxatin
  • 產品簡介:Erbitux
  • 產品簡介:Lonsurf
  • 產品簡介:Stivarga
  • 產品簡介:Vectibix
  • 產品簡介:Xeloda
  • 產品簡介:Zaltrap

開發平台:大腸癌

  • 摘要整理
  • 臨床實驗平台概要
  • 產品簡介 (後期) :CPP-1X/sulindac
  • 產品簡介 (後期) :Imprime PGG
  • 產品簡介 (後期) :Keytruda
  • 產品簡介 (後期) :MGN1703
  • 產品簡介 (後期) :Ofev
  • 產品簡介 (後期) :OncoVAX
  • 產品簡介 (後期) :Xilonix
  • 產品簡介 (後期) :masitinib

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC10877

Pipeline candidates for the colorectal cancer market will pursue novel mechanisms of action to distinguish themselves in an increasingly crowded market.

This report addresses the following questions:

  • How are new therapies differentiating themselves in the increasingly crowded and price-sensitive CRC market?
  • How will looming patent expiries for Avastin and Erbitux affect the competitive dynamics within CRC?
  • What kind of impact will Merck's PD-1inhibitor Keytruda have in this indication?
  • Which patient populations still represent an area of high unmet need

TABLE OF CONTENTS

FORECAST: COLORECTAL CANCER

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Methodology and Market Definition
  • 4. Avastin (bevacizumab)
  • 5. CPP-1X (eflornithine/sulindac)
  • 6. Cyramza (ramucirumab)
  • 7. Erbitux (cetuximab)
  • 8. Imprime PGG
  • 9. Keytruda (pembrolizumab)
  • 10. Lonsurf (trifluridine/tipiracil)
  • 11. Masitinib
  • 12. MGN1703 (lefitolimod)
  • 13. Ofev (nintedanib)
  • 14. OncoVAX
  • 15. Stivarga (regorafenib)
  • 16. TS-1 (gimeracil/oteracil potassium/tegafur)
  • 17. Vectibix (panitumumab)
  • 18. Xilonix
  • 19. Zaltrap (aflibercept)
  • 20. Primary Research Methodology

TREATMENT: COLORECTAL CANCER IN THE US, JAPAN, AND 5EU

  • 21. Executive Summary
  • 22. Disease Definition and Diagnosis
  • 23. Patient Segmentation
  • 24. Current Treatment Options
  • 25. Stage I and Stage II
  • 26. Stage III
  • 27. Stage IV
  • 28. Survey Methodology

EPIDEMIOLOGY: COLORECTAL CANCER IN THE US, JAPAN, AND 5EU

  • 29. Executive Summary
  • 30. Disease Definition
  • 31. Global Variation
  • 32. Risk Factors
  • 33. Sources and Methodology
  • 34. Forecast
  • 35. Epidemiologist Insight
  • 36. Strengths and Limitations
  • 37. Bibliography

MARKETED DRUGS: COLORECTAL CANCER

  • 38. Executive Summary
  • 39. Product Overview
  • 40. Other Marketed Drugs for Colorectal Cancer
  • 41. Product profile: Avastin
  • 42. Product profile: Camptosar
  • 43. Product profile: Cyramza
  • 44. Product profile: Eloxatin
  • 45. Product profile: Erbitux
  • 46. Product profile: Lonsurf
  • 47. Product profile: Stivarga
  • 48. Product profile: Vectibix
  • 49. Product profile: Xeloda
  • 50. Product profile: Zaltrap

PIPELINE: COLORECTAL CANCER

  • 51. Executive Summary
  • 52. Clinical Pipeline Overview
  • 53. Product profile (late stage): CPP-1X/sulindac
  • 54. Product profile (late stage): Imprime PGG
  • 55. Product profile (late stage): Keytruda
  • 56. Product profile (late stage): MGN1703
  • 57. Product profile (late stage): Ofev
  • 58. Product profile (late stage): OncoVAX
  • 59. Product profile (late stage): Xilonix
  • 60. Product profile (late stage): masitinib
Back to Top